Molecular Signatures of TMS Response in Treatment-Resistant Depression

NARecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

June 15, 2025

Primary Completion Date

December 15, 2026

Study Completion Date

June 1, 2027

Conditions
Major Depression Disorder
Interventions
DEVICE

TMS

"Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation technique approved for the treatment of major depressive disorder (MDD), particularly in individuals with treatment-resistant depression (TRD). TMS targets the left dorsolateral prefrontal cortex (DLPFC), a brain region often underactive in depression, and modulates neural activity through magnetic pulses.~This study aims to evaluate the effects of TMS on plasma proteomic and metabolomic profiles in patients with TRD. Participants will undergo 20 sessions of intermittent theta burst stimulation (iTBS) over four weeks. Blood samples will be collected before and after treatment to identify molecular changes associated with clinical response. Healthy controls will provide single-time-point blood samples for baseline comparison. Findings may support the development of biomarker-based strategies for personalized treatment in psychiatry."

Trial Locations (2)

06000

RECRUITING

Gulhane Training and Research Hospital, Ankara

06300

RECRUITING

Gulhane Training and Research Hospital, Ankara

All Listed Sponsors
lead

Gulhane Training and Research Hospital

OTHER_GOV

NCT07039370 - Molecular Signatures of TMS Response in Treatment-Resistant Depression | Biotech Hunter | Biotech Hunter